The Modern Urology Pipeline: Career Trajectories of Recent Residency Graduates.
The Modern Urology Pipeline: Career Trajectories of Recent Residency Graduates. Urol Pract. 2026 Sep 08; 101097UPJ0000000000001086.
PMID: 42708580
Rising Active Surveillance/Observation Rates and Regimen Intensification in Young Men: A Retrospective Cohort Study of National Commercial Health Insurance Claims Data.
Rising Active Surveillance/Observation Rates and Regimen Intensification in Young Men: A Retrospective Cohort Study of National Commercial Health Insurance Claims Data. Urology. 2026 Sep 01.
PMID: 42679931
Pathologic failure and salvage approaches following focal therapy for localized prostate cancer.
Pathologic failure and salvage approaches following focal therapy for localized prostate cancer. Can J Urol. 2026 Aug 21; 33(4):799-810.
PMID: 42682046
Single-port vs. multi-port robotic radical prostatectomy: an umbrella review of meta-analyses.
Single-port vs. multi-port robotic radical prostatectomy: an umbrella review of meta-analyses. J Robot Surg. 2026 Aug 11; 20(1).
PMID: 42579231
Trans-perineal prostate biopsy-Prognostic factors for "no prostate tissue" in biopsy cores.
Trans-perineal prostate biopsy-Prognostic factors for "no prostate tissue" in biopsy cores. Urol Oncol. 2026 Oct; 44(10):783-788.
PMID: 42557190
Water Vapor Therapy for the Management of Prostate Cancer: The VAPOR 2 Study Initial Results of Ablative Efficacy and Toxicity.
Water Vapor Therapy for the Management of Prostate Cancer: The VAPOR 2 Study Initial Results of Ablative Efficacy and Toxicity. J Urol. 2026 Oct; 216(4):527-539.
PMID: 42269147
Clinical outcomes of benign prostatic hyperplasia surgery in men with detrusor underactivity versus normal contractility: a systematic review and meta-analysis.
Clinical outcomes of benign prostatic hyperplasia surgery in men with detrusor underactivity versus normal contractility: a systematic review and meta-analysis. Int Urol Nephrol. 2026 Oct; 58(10):4015-4025.
PMID: 42115505
Phase II trial protocol of focal prostate ablation combined with androgen deprivation therapy for prostate cancer treatment.
Phase II trial protocol of focal prostate ablation combined with androgen deprivation therapy for prostate cancer treatment. PLoS One. 2025; 20(12):e0337828.
PMID: 41401176
Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial.
Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial. Eur Urol. 2026 Jan; 89(1):57-68.
PMID: 40685282
Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer.
Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer. N Engl J Med. 2025 Jun 19; 392(23):2346-2356.
PMID: 40532152